• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Keywords » peptide-drug conjugates

Items Tagged with 'peptide-drug conjugates'

ARTICLES

Nibec stock soars 30% on $435M peptide deal with US biotech

June 3, 2025
By Marian (YoonJee) Chu
No Comments
Nibec Co. Ltd. announced May 28 the signing of a potential $435 million license deal for NP-201, its phase II-ready peptide-based pulmonary fibrosis therapy candidate, with an undisclosed U.S.-based biotech company.
Read More

Nibec stock soars 30% on $435M peptide deal with US biotech

May 29, 2025
By Marian (YoonJee) Chu
No Comments
Nibec Co. Ltd. announced May 28 the signing of a potential $435 million license deal for NP-201, its phase II-ready peptide-based pulmonary fibrosis therapy candidate, with an undisclosed U.S.-based biotech company.
Read More
Dollar sign droplet above test tube
Cancer

Series A financing at Proteinqure to advance peptide-drug conjugate into clinic for TNBC

May 29, 2025
No Comments
Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC). The funds will also be used to advance additional pipeline programs in neurology and nephrology.
Read More
Art concept for drug research
Cancer

Novel peptide-drug conjugate achieves durable tumor retention with favorable safety profile

May 22, 2025
No Comments
Peptide-drug conjugates (PDCs) are emerging as a promising alternative to antibody-drug conjugates (ADCs), offering enhanced tumor penetration and reduced immunogenicity. Carbonic anhydrase IX (CAIX) and epidermal growth factor receptor (EGFR) are both well-validated targets in oncology due to their role in cancer cell survival, invasion and migration.
Read More
Cancer

Haisco Pharmaceutical describes new peptide-drug conjugates

May 5, 2025
Haisco Pharmaceutical Group Co. Ltd. has identified peptide-drug conjugates comprising a peptide targeting integrin αvβ3 (vitronectin) covalently bound to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Read More
Cancer

Mainline Biosciences discovers new peptide-drug conjugates for cancer

April 2, 2025
Mainline Biosciences (Shanghai) Co. Ltd. has described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound to cytotoxic agents through a linker reported to be useful for the treatment of cancer.
Read More
Cancer

Cybrexa’s new peptide-drug conjugate shows strong antitumor activity

March 11, 2025
Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different mechanisms are advancing in the oncologic pipeline. Researchers from Cybrexa Therapeutics Inc. presented new preclinical data on CBX-15, a peptide-drug conjugate (PDC) consisting of a pH-low insertion peptide (pHLIP) linked to monomethyl auristatin E (MMAE).
Read More
Cancer

AVA-6103 for the treatment of FAP-positive cancer by targeting topoisomerase

Nov. 6, 2024
Avacta Life Sciences (Avacta Group plc) presented preclinical data on AVA-6103, a second-generation Precision peptide-drug conjugate, being developed for the potential treatment of cancer. AVA-6103 was developed using the company’s proprietary Precision technology incorporating a dipeptide specifically cleaved by fibroblast activation protein α (FAPα) leading to tumor-specific delivery of exatecan directly into the tumor cells.
Read More
Cancer

Aposense discovers SAPK1 (JNK) inhibitors

Oct. 23, 2024
Aposense Ltd. has prepared and tested peptide-drug conjugates comprising a cell-penetrating peptide covalently bound to the therapeutically affective amino acid sequence (SAPK1 [JNK] inhibitors) linked to sterol derivatives through a linker reported to be useful for the treatment of cancer.
Read More
Microscope with laptop displaying histology image.
Cancer

Avacta adds new preclinical oncology assets to pipeline

Oct. 17, 2024
Avacta Group plc has expanded its pipeline of Precision-enabled drug conjugates with the addition of two novel preclinical oncology assets, AVA-6103 and AVA-7100. The company’s peptide-drug conjugates (PDCs) comprise a payload linked to the Precision peptide, which is cleaved only within the tumor by the action of fibroblast activation protein (FAP).
Read More
More Articles Tagged with 'peptide-drug conjugates'

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 14, 2025.
  • Circode executives

    Circode applies circRNA to heart disease drug R&D, in vivo CAR T

    BioWorld
    Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...
  • Merger-arrows-black-white.png

    BD’s biosciences & diagnostics unit in $17.5B merger with Waters

    BioWorld MedTech
    Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...
  • Art concept for gene therapy research

    Ultragenyx hit again, this time with a CRL in rare disease

    BioWorld
    Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe